Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA-Reference-Cited by-同舟云学术

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

Published:2023-01-11 Issue:2 Volume:12 Page:607-621
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Cheng Mindy M.,Reyes Carolina,Satram Sacha,Birch Helen,Gibbons Daniel C.,Drysdale Myriam,Bell Christopher F.,Suyundikov Anvar,Ding Xiao,Maher M. Cyrus,Yeh Wendy,Telenti Amalio,Corey Lawrence

Funder

Vir Biotechnology

GlaxoSmithKline

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-022-00755-0.pdf

Reference20 articles.

1. World Health Organization. Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 22 Sep 2022.

2. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21(2):167–79. https://doi.org/10.1007/s10238-020-00671-y.

3. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19 related mortality, 2020–21. Lancet. 2022;399(10334):1513–36. https://doi.org/10.1016/S0140-6736(21)02796-3.

4. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. News Release. FDA; May, 26, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19. Accessed 20 May 2022.

5. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–50. https://doi.org/10.1056/NEJMoa2107934.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence of sotrovimab effectiveness for preventing severe outcomes in patients with COVID-19: A quality improvement propensity-matched retrospective cohort study of a pan-provincial program in Alberta, Canada;International Journal of Infectious Diseases;2024-09

2. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records;PLOS ONE;2024-07-16

3. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study;Current Medical Research and Opinion;2024-07-08

4. Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST);Journal of Infection and Public Health;2024-07

5. An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity;Vaccines;2024-06-18